

Tjip S Van Der Werf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4705223/publications.pdf>

Version: 2024-02-01

214
papers

7,866
citations

57758

44
h-index

66911

78
g-index

217
all docs

217
docs citations

217
times ranked

7820
citing authors

#	ARTICLE	IF	CITATIONS
1	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 466-473.	3.0	6
2	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	3.2	4
3	Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	5
4	Artificial Intelligence to Guide Empirical Antimicrobial Therapy—Ready for Prime Time?. <i>Clinical Infectious Diseases</i> , 2021, 72, e856-e858.	5.8	2
5	COPD-Lower Respiratory Tract Infection Visual Analogue Score (c-LRTI-VAS) validation in stable and exacerbated patients with COPD. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000761.	3.0	1
6	Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana. <i>BMC Infectious Diseases</i> , 2021, 21, 331.	2.9	3
7	Sarcoidosis presenting with glazy mucoid sputum and dyspnea: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 232.	0.8	1
8	Ganciclovir therapeutic drug monitoring in transplant recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2356-2363.	3.0	23
9	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. <i>BMJ Open</i> , 2021, 11, e049777.	1.9	4
10	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	15
11	Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. <i>European Respiratory Journal</i> , 2020, 56, 2000803.	6.7	8
12	Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review. <i>BMJ Open</i> , 2020, 10, e034940.	1.9	2
13	Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data. <i>European Respiratory Journal</i> , 2020, 56, 2001086.	6.7	3
14	Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. <i>BMJ Open</i> , 2020, 10, e035350.	1.9	4
15	Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1259-1267.	13.7	71
16	Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin. <i>European Respiratory Journal</i> , 2020, 55, 1901903.	6.7	12
17	Corticosteroid therapy for the management of paradoxical inflammatory reaction in patients with pulmonary tuberculosis. <i>Infection</i> , 2020, 48, 641-645.	4.7	4
18	The phylogenetic landscape and nosocomial spread of the multidrug-resistant opportunist <i>Stenotrophomonas maltophilia</i> . <i>Nature Communications</i> , 2020, 11, 2044.	12.8	76

#	ARTICLE	IF	CITATIONS
19	Pharmacologic management of <i>Mycobacterium ulcerans</i> infection. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 391-401.	3.1	16
20	Diagnosis of tuberculosis through breath test: A systematic review. <i>EBioMedicine</i> , 2019, 46, 202-214.	6.1	44
21	Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?. <i>European Respiratory Journal</i> , 2019, 54, 1901597.	6.7	0
22	Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007866.	3.0	8
23	Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. <i>Mycoses</i> , 2019, 62, 698-705.	4.0	17
24	Impact of radiographic screening of >34€Š000 asylum seeker children. <i>European Respiratory Journal</i> , 2019, 54, 1900579.	6.7	4
25	Sensitivity and specificity of an electronic nose in diagnosing pulmonary tuberculosis among patients with suspected tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0217963.	2.5	24
26	Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	19
27	Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1445-1454.	3.5	19
28	Reduced moxifloxacin exposure in patients with tuberculosis and diabetes. <i>European Respiratory Journal</i> , 2019, 54, 1900373.	6.7	7
29	The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007273.	3.0	2
30	Random glucose sampling as screening tool for diabetes among disadvantaged tuberculosis patients residing in urban slums in India. <i>ERJ Open Research</i> , 2019, 5, 00025-2019.	2.6	0
31	CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. <i>European Respiratory Journal</i> , 2019, 53, 1802014.	6.7	66
32	Tuberculosis-Related Malnutrition: Public Health Implications. <i>Journal of Infectious Diseases</i> , 2019, 220, 340-341.	4.0	19
33	Sensitivity and specificity of routine diagnostic work-up for tuberculosis in lung clinics in Yogyakarta, Indonesia: a cohort study. <i>BMC Public Health</i> , 2019, 19, 363.	2.9	15
34	Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
35	Global Epidemiology of Buruli Ulcer, 2010–2017, and Analysis of 2014 WHO Programmatic Targets. <i>Emerging Infectious Diseases</i> , 2019, 25, 2183-2190.	4.3	41
36	<p>Multidrug-Resistant Infections Among Hospitalized Adults With Community-Acquired Pneumonia In An Indonesian Tertiary Referral Hospital<p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 3663-3675.	2.7	6

#	ARTICLE	IF	CITATIONS
37	Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 59-65.	2.0	5
38	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019, 54, 1900580.	6.7	21
39	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 253-254.	2.0	5
40	1538. Who Will Benefit From Therapeutic Drug Monitoring of Ganciclovir?. <i>Open Forum Infectious Diseases</i> , 2019, 6, S560-S561.	0.9	0
41	A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs. <i>Clinical Pharmacokinetics</i> , 2019, 58, 747-766.	3.5	53
42	High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of <i>Mycobacterium ulcerans</i> Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
43	Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
44	Posaconazole trough concentrations are not influenced by inflammation: A prospective study. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 325-329.	2.5	9
45	Antimicrobial Treatment of <i>Mycobacterium ulcerans</i> Infection. , 2019, , 203-220.		8
46	In Vivo Imaging of Bioluminescent <i>Mycobacterium ulcerans</i> : A Tool to Refine the Murine Buruli Ulcer Tail Model. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 1312-1321.	1.4	9
47	Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 650-656.	9.1	31
48	Lack of penetration of amikacin into saliva of tuberculosis patients. <i>European Respiratory Journal</i> , 2018, 51, 1702024.	6.7	9
49	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702490.	6.7	7
50	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. <i>Clinical Infectious Diseases</i> , 2018, 67, 1743-1749.	5.8	19
51	Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited. <i>Clinical Infectious Diseases</i> , 2018, 67, 835-836.	5.8	4
52	Risk factors contributing to a low darunavir plasma concentration. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 456-461.	2.4	4
53	Treatment for Buruli ulcer: the long and winding road to antimicrobials-first. <i>The Cochrane Library</i> , 2018, 12, ED000128.	2.8	5
54	Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25

#	ARTICLE	IF	CITATIONS
55	Pathogen-based precision medicine for drug-resistant tuberculosis. <i>PLoS Pathogens</i> , 2018, 14, e1007297.	4.7	43
56	Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet, The</i> , 2018, 392, 821-834.	13.7	452
57	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	8.4	96
58	Variability and cost implications of three generations of the Roche LightCycler® 480. <i>PLoS ONE</i> , 2018, 13, e0190847.	2.5	5
59	Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 376-378.	1.4	1
60	Virulence potential of <i>Staphylococcus aureus</i> isolates from Buruli ulcer patients. <i>International Journal of Medical Microbiology</i> , 2017, 307, 223-232.	3.6	15
61	Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
62	Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601612.	6.7	16
63	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2017, 49, 1601724.	6.7	20
64	Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 688-694.	2.5	35
65	Recombinant BCG Expressing ESX-1 of <i>Mycobacterium marinum</i> Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. <i>Cell Reports</i> , 2017, 18, 2752-2765.	6.4	98
66	Neurological and functional recovery in tuberculosis patients with spinal cord injury in The Netherlands. <i>NeuroRehabilitation</i> , 2017, 40, 439-445.	1.3	8
67	Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug/extensively-resistant tuberculosis (M/XDR-TB) in Europe: A tuberculosis network European Trialsgroup (TBNET) study. <i>Respiratory Medicine</i> , 2017, 132, 68-75.	2.9	7
68	Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2325-2329.	2.4	5
69	Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. <i>Respiratory Medicine</i> , 2017, 131, 118-124.	2.9	34
70	Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events. <i>Aids</i> , 2017, 31, 241-246.	2.2	8
71	Low Caspofungin Exposure in Patients in Intensive Care Units. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	41
72	Voriconazole metabolism is influenced by severe inflammation: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 261-267.	3.0	113

#	ARTICLE	IF	CITATIONS
73	Bioavailability of voriconazole in hospitalised patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 243-246.	2.5	19
74	Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review. <i>Frontiers in Immunology</i> , 2017, 8, 772.	4.8	64
75	Methicillin Resistant <i>Staphylococcus aureus</i> Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings. <i>Frontiers in Microbiology</i> , 2017, 8, 1906.	3.5	11
76	Epidemiology of <i>Staphylococcus aureus</i> in a burn unit of a tertiary care center in Ghana. <i>PLoS ONE</i> , 2017, 12, e0181072.	2.5	25
77	Yellow fever in a traveller returning from Suriname to the Netherlands, March 2017. <i>Eurosurveillance</i> , 2017, 22, .	7.0	17
78	Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis. <i>Clinical Infectious Diseases</i> , 2016, 62, civ921.	5.8	38
79	Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C₂H₂ measurements. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1695-1696.	1.2	3
80	Former Buruli Ulcer Patients's™ Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005261.	3.0	21
81	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. <i>PLoS ONE</i> , 2016, 11, e0149768.	2.5	25
82	Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. <i>PLoS ONE</i> , 2016, 11, e0166030.	2.5	6
83	Implementing tuberculosis entry screening for asylum seekers: the Groningen experience. <i>European Respiratory Journal</i> , 2016, 48, 261-264.	6.7	21
84	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. <i>European Respiratory Journal</i> , 2016, 48, 1800-1802.	6.7	9
85	Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2691-2703.	3.0	28
86	High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert <i>Mycobacterium tuberculosis</i> /rifampicin in Ghana. <i>International Journal of Mycobacteriology</i> , 2016, 5, 226-230.	0.6	22
87	The Application of Modern Dressings to Buruli Ulcers: Results from a Pilot Implementation Project in Ghana. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 60-62.	1.4	9
88	Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. <i>European Respiratory Journal</i> , 2016, 47, 1288-1290.	6.7	12
89	Prolonged pyrexia and subtle skin lesions: polyarteritis nodosa. <i>Lancet, The</i> , 2016, 387, 1025-1026.	13.7	3
90	PET/CT imaging of <i>Mycobacterium tuberculosis</i> infection. <i>Clinical and Translational Imaging</i> , 2016, 4, 131-144.	2.1	98

#	ARTICLE	IF	CITATIONS
91	Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring. <i>International Journal of Mycobacteriology</i> , 2016, 5, S44-S45.	0.6	11
92	Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients. <i>European Respiratory Journal</i> , 2016, 48, 1237-1239.	6.7	8
93	Experiences of Pain and Expectations for Its Treatment Among Former Buruli Ulcer Patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1011-1015.	1.4	8
94	Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 313-318.	2.0	9
95	Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV. <i>European Respiratory Journal</i> , 2016, 48, 932-934.	6.7	8
96	Reply to Verhaeghe et al: Table 1.. <i>Clinical Infectious Diseases</i> , 2016, 63, 146-147.	5.8	0
97	Validation of a visual analogue score (<sc>LRTI&E</sc>VAS</sc>) in non&E<sc>CF</sc> bronchiectasis. <i>Clinical Respiratory Journal</i> , 2016, 10, 168-175.	1.6	14
98	Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 517-518.	1.4	4
99	Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naïve TB patients: a randomized cross-over trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 703-710.	3.0	41
100	Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics. <i>European Respiratory Journal</i> , 2016, 47, 1867-1869.	6.7	59
101	End TB with precision treatment!. <i>European Respiratory Journal</i> , 2016, 47, 680-682.	6.7	45
102	Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2016, 47, 1229-1234.	6.7	30
103	Genetic Susceptibility and Predictors of Paradoxical Reactions in Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004594.	3.0	22
104	High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015. <i>PLoS ONE</i> , 2016, 11, e0154791.	2.5	30
105	Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 766-771.	2.0	29
106	Pain Associated with Wound Care Treatment among Buruli Ulcer Patients from Ghana and Benin. <i>PLoS ONE</i> , 2015, 10, e0119926.	2.5	10
107	Molecular Characterization of Staphylococcus aureus Isolates Transmitted between Patients with Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004049.	3.0	12
108	Assessment and Treatment of Pain during Treatment of Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0004076.	3.0	8

#	ARTICLE	IF	CITATIONS
109	Evaluation of macrolides for possible use against multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2015, 46, 444-455.	6.7	20
110	The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. <i>European Respiratory Journal</i> , 2015, 45, 569-571.	6.7	20
111	Limited-Sampling Strategies for Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1177-1181.	3.2	10
112	Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5675-5680.	3.2	28
113	Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4907-4913.	3.2	37
114	In-vitro Activity of Avermectins against <i>Mycobacterium ulcerans</i> . <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003549.	3.0	46
115	Genetic Diversity of <i>Staphylococcus aureus</i> in Buruli Ulcer. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003421.	3.0	21
116	Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. <i>Vaccine</i> , 2015, 33, 3193-3199.	3.8	78
117	Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. <i>European Respiratory Journal</i> , 2015, 46, 1205-1207.	6.7	47
118	Buruli Ulcer Control in a Highly Endemic District in Ghana: Role of Community-Based Surveillance Volunteers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 115-117.	1.4	35
119	The Never Ending Struggle Against Development of Drug Resistance. <i>Clinical Infectious Diseases</i> , 2015, 61, 137-138.	5.8	0
120	Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2474-2474.	3.2	7
121	Low but Sufficient Anidulafungin Exposure in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 304-308.	3.2	24
122	Persisting Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3303.	3.0	27
123	Good Quality of Life in Former Buruli Ulcer Patients with Small Lesions: Long-Term Follow-up of the BURULICO Trial. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2964.	3.0	18
124	Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2739.	3.0	56
125	Contribution of the Community Health Volunteers in the Control of Buruli Ulcer in Benin. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3200.	3.0	38
126	Psychometric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3254.	3.0	10

#	ARTICLE	IF	CITATIONS
127	Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Postingestion in Relation to Treatment Response. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 628-628.	3.2	4
128	Optimization of Standard In-House 24-Locus Variable-Number Tandem-Repeat Typing for <i>Mycobacterium tuberculosis</i> and Its Direct Application to Clinical Material. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1338-1342.	3.9	27
129	Therapeutic vaccines for tuberculosisâ€”A systematic review. <i>Vaccine</i> , 2014, 32, 3162-3168.	3.8	66
130	Inflammation Is Associated with Voriconazole Trough Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7098-7101.	3.2	81
131	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. <i>Clinical Infectious Diseases</i> , 2014, 59, 1364-1374.	5.8	116
132	In vitro synergy between linezolid and clarithromycin against <i>Mycobacterium tuberculosis</i> . <i>European Respiratory Journal</i> , 2014, 44, 808-811.	6.7	14
133	Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2014, 43, 884-897.	6.7	55
134	Wound Care in Buruli Ulcer Disease in Ghana and Benin. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 313-318.	1.4	28
135	A systematic review of a single-class maintenance strategy with nucleoside reverse transcriptase inhibitors in HIV/AIDS. <i>Antiviral Therapy</i> , 2014, 19, 625-636.	1.0	3
136	Oral treatment for patients with Buruli ulcer co-infected with HIV. <i>Aids</i> , 2014, 28, 797-798.	2.2	2
137	Incidence of Thrombotic Events in Patients Admitted to a Dedicated Tuberculosis Center in the Netherlands. <i>Blood</i> , 2014, 124, 2860-2860.	1.4	0
138	Comparison of 14 Molecular Assays for Detection of <i>Mycobacterium tuberculosis</i> Complex in Bronchoalveolar Lavage Fluid. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3505-3511.	3.9	19
139	Rifampicin and moxifloxacin for tuberculous meningitis. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 568-569.	9.1	1
140	The role of <i>Streptococcus pneumoniae</i> in community-acquired pneumonia among adults in Europe: a meta-analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013, 32, 305-316.	2.9	86
141	Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. <i>Medical Microbiology and Immunology</i> , 2013, 202, 95-104.	4.8	63
142	Towards Rational Use of Antibiotics for Suspected Secondary Infections in Buruli Ulcer Patients. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2010.	3.0	24
143	Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 504-512.	6.7	55
144	Serum Levels of Neopterin during Antimicrobial Treatment for <i>Mycobacterium ulcerans</i> Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 498-500.	1.4	5

#	ARTICLE	IF	CITATIONS
145	Dried Blood Spot Analysis Suitable for Therapeutic Drug Monitoring of Voriconazole, Fluconazole, and Posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4999-5004.	3.2	45
146	Drug concentration in lung tissue in multidrug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2013, 42, 1750-1752.	6.7	23
147	Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Non-Cystic Fibrosis Bronchiectasis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1251.	7.4	421
148	Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. <i>European Respiratory Journal</i> , 2013, 42, 1614-1621.	6.7	59
149	Perceptions on the Effectiveness of Treatment and the Timeline of Buruli Ulcer Influence Pre-Hospital Delay Reported by Healthy Individuals. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2014.	3.0	14
150	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
151	Paradoxical Responses After Start of Antimicrobial Treatment in <i>Mycobacterium ulcerans</i> Infection. <i>Clinical Infectious Diseases</i> , 2012, 54, 519-526.	5.8	91
152	D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia. A secondary analysis of a randomised clinical trial. <i>European Journal of Internal Medicine</i> , 2012, 23, 436-441.	2.2	76
153	<i>Mycobacterium bovis</i> infection in a young Dutch adult: transmission from an elderly human source?. <i>Medical Microbiology and Immunology</i> , 2012, 201, 397-400.	4.8	4
154	Nutritional status and vitamin D3 during antimicrobial treatment. <i>Lancet</i> , The, 2011, 377, 1407-1408.	13.7	5
155	Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 350-354.	2.0	30
156	Immunology in Tuberculosis: Challenges in Monitoring of Disease Activity and Identifying Correlates of Protection. <i>Current Pharmaceutical Design</i> , 2011, 17, 2853-2862.	1.9	11
157	Unusual Cluster of HIV Type 1 Dual Infections in Groningen, The Netherlands. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 429-433.	1.1	10
158	Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. <i>British Journal of Nutrition</i> , 2011, 105, 400-408.	2.3	35
159	Association between <i>Faecalibacterium prausnitzii</i> and dietary fibre in colonic fermentation in healthy human subjects. <i>British Journal of Nutrition</i> , 2010, 104, 693-700.	2.3	172
160	Pandemic influenza and pediatric intensive care*. <i>Pediatric Critical Care Medicine</i> , 2010, 11, 185-198.	0.5	11
161	Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 97-101.	2.0	55
162	Impact of digestive and oropharyngeal decontamination on the intestinal microbiota in ICU patients. <i>Intensive Care Medicine</i> , 2010, 36, 1394-1402.	8.2	61

#	ARTICLE	IF	CITATIONS
163	Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the Netherlands. <i>Clinical Therapeutics</i> , 2010, 32, 1517-1532.	2.5	44
164	Clarithromycin Significantly Increases Linezolid Serum Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5418-5419.	3.2	31
165	A Genotypic Approach for Detection, Identification, and Characterization of Drug Resistance in <i>Mycobacterium ulcerans</i> in Clinical Samples and Isolates from Ghana. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 1059-1065.	1.4	25
166	Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in Antiretroviral Therapy-Naïve Patients: FREE Randomized Trial Interim Results. <i>AIDS Patient Care and STDs</i> , 2010, 24, 361-366.	2.5	9
167	Dosing Ethambutol in Obese Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4044-4045.	3.2	7
168	Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients. <i>Clinical Pharmacokinetics</i> , 2010, 49, 559-565.	3.5	50
169	Physicians' and nurses' opinions on selective decontamination of the digestive tract and selective oropharyngeal decontamination: a survey. <i>Critical Care</i> , 2010, 14, R132.	5.8	11
170	Antimicrobial treatment for early, limited <i>Mycobacterium ulcerans</i> infection: a randomised controlled trial. <i>Lancet, The</i> , 2010, 375, 664-672.	13.7	258
171	Antimicrobial drugs for Buruli ulcer – Authors' reply. <i>Lancet, The</i> , 2010, 375, 1873-1874.	13.7	2
172	Efficacy of Corticosteroids in Community-acquired Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 975-982.	5.6	262
173	Comparative Study of the Sensitivity of Different Diagnostic Methods for the Laboratory Diagnosis of Buruli Ulcer Disease. <i>Clinical Infectious Diseases</i> , 2009, 48, 1055-1064.	5.8	68
174	Buruli ulcer disease: prospects for a vaccine. <i>Medical Microbiology and Immunology</i> , 2009, 198, 69-77.	4.8	42
175	Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 81, 82-87.	1.4	49
176	Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 81, 82-7.	1.4	34
177	Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2008, 102, 912-920.	1.8	48
178	Pandemic Influenza and Excess Intensive-Care Workload. <i>Emerging Infectious Diseases</i> , 2008, 14, 1518-1525.	4.3	24
179	Bronchoscopic diagnosis of pulmonary infiltrates in granulocytopenic patients with hematologic malignancies: BAL versus PSB and PBAL. <i>Respiratory Medicine</i> , 2007, 101, 317-325.	2.9	66
180	Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: A survey. <i>Respiratory Medicine</i> , 2007, 101, 2091-2098.	2.9	48

#	ARTICLE	IF	CITATIONS
181	Pandemic Influenza and Hospital Resources. <i>Emerging Infectious Diseases</i> , 2007, 13, 1714-1719.	4.3	40
182	Automated erythrocytapheresis in severe falciparum malaria: A critical appraisal. <i>Acta Tropica</i> , 2006, 98, 201-206.	2.0	30
183	An 18-Year-Old Man With Rapidly Progressive Multiorgan Failure After a Positive Mononucleosis Spot Test Result. <i>Chest</i> , 2006, 130, 291-295.	0.8	2
184	Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2005, 99, 196-201.	1.8	29
185	Lung transplantation for acute respiratory failure in rapidly progressive idiopathic pulmonary fibrosis. <i>Transplant International</i> , 2005, 18, 890-891.	1.6	2
186	Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. <i>Tropical Medicine and International Health</i> , 2005, 10, 1251-1257.	2.3	50
187	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. <i>Vaccine Journal</i> , 2005, 12, 125-129.	3.1	47
188	Risk Factors for Buruli Ulcer Disease (<i>Mycobacterium ulcerans</i> Infection): Results from a Case-Control Study in Ghana. <i>Clinical Infectious Diseases</i> , 2005, 40, 1445-1453.	5.8	138
189	<i>Mycobacterium ulcerans</i> disease. <i>Bulletin of the World Health Organization</i> , 2005, 83, 785-91.	3.3	114
190	Immunoglobulin M Antibody Responses to <i>Mycobacterium ulcerans</i> Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. <i>Vaccine Journal</i> , 2004, 11, 387-391.	2.6	21
191	p38-MAPK inhibition and endotoxin induced tubular dysfunction in men. <i>Journal of Endotoxin Research</i> , 2004, 10, 402-405.	2.5	4
192	Ultrasound of the lung: just imagine. <i>Intensive Care Medicine</i> , 2004, 30, 183-184.	8.2	43
193	Cardiac troponin I release and cytokine response during experimental human endotoxaemia. <i>Intensive Care Medicine</i> , 2003, 29, 1598-1600.	8.2	41
194	Assessment of functional limitations caused by <i>Mycobacterium ulcerans</i> infection: towards a Buruli Ulcer Functional Limitation Score. <i>Tropical Medicine and International Health</i> , 2003, 8, 90-96.	2.3	41
195	Buruli ulcer: differences in treatment outcome between two centres in Ghana. <i>Acta Tropica</i> , 2003, 88, 51-56.	2.0	40
196	Mycolactones and <i>Mycobacterium ulcerans</i> disease. <i>Lancet, The</i> , 2003, 362, 1062-1064.	13.7	78
197	Analysis of an IS 2404 -Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. <i>Journal of Clinical Microbiology</i> , 2003, 41, 794-797.	3.9	38
198	Histopathologic Features of <i>Mycobacterium ulcerans</i> Infection. <i>Emerging Infectious Diseases</i> , 2003, 9, 651-656.	4.3	134

#	ARTICLE	IF	CITATIONS
199	Prone Positioning of Patients with Acute Respiratory Failure. <i>New England Journal of Medicine</i> , 2002, 346, 295-297.	27.0	11
200	Inhibition of p38 mitogen-activated protein kinase: Dose-dependent suppression of leukocyte and endothelial response after endotoxin challenge in humans*. <i>Critical Care Medicine</i> , 2002, 30, 841-845.	0.9	29
201	Availability of drugs to admitted patients in Yemeni public hospitals. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 79-80.	1.9	0
202	Beliefs and attitudes toward Buruli ulcer in Ghana.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 207-213.	1.4	131
203	Fulminant necrotizing fasciitis and nonsteroidal antiinflammatory drugs. <i>Intensive Care Medicine</i> , 2001, 27, 1831-1831.	8.2	27
204	Chloroquine- and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo- a pilot study in rural Zambia. <i>Tropical Medicine and International Health</i> , 2000, 5, 692-695.	2.3	27
205	Antidepressants self-poisoning and ICU admissions in a university hospital in The Netherlands. <i>International Journal of Clinical Pharmacy</i> , 2000, 22, 92-95.	1.4	23
206	A narrow escape: surviving massive pulmonary thromboembolism due to a persistently patent foramen ovale. <i>Intensive Care Medicine</i> , 2000, 26, 1400-1400.	8.2	4
207	Semirecumbent position in intensive care patients. <i>Lancet, The</i> , 2000, 355, 1013-1014.	13.7	5
208	Condition on arrival of transferred critically ill patients. <i>Netherlands Journal of Medicine</i> , 2000, 57, 180-184.	0.5	9
209	Non-surgical treatment of purulent pericarditis, due to non-encapsulated <i>Haemophilus influenzae</i> , in an immunocompromised patient. <i>Netherlands Journal of Medicine</i> , 1999, 55, 151-154.	0.5	6
210	<i>Mycobacterium ulcerans</i> infection. <i>Lancet, The</i> , 1999, 354, 1013-1018.	13.7	271
211	Community acquired pneumonia caused by <i>M. tuberculosis</i> diagnosis with CT. <i>European Journal of Radiology</i> , 1997, 24, 253-256.	2.6	1
212	Atresia of a solitary pulmonary vein. <i>Cardiology in the Young</i> , 1995, 5, 350-353.	0.8	3
213	Pulmonary Tuberculosis Complicated by Bronchopleural Fistula. <i>Tropical Doctor</i> , 1989, 19, 31-33.	0.5	2
214	DIABETES IN RURAL WEST AFRICA. <i>Lancet, The</i> , 1987, 330, 638-639.	13.7	0